Evidence map›Paper›PMID 25975287›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

PDGFRA-mutant syndrome.

Riccardo Ricci, Maurizio Martini, Tonia Cenci, Arnaldo Carbone, Paola Lanza, Alberto Biondi, Guido Rindi, Alessandra Cassano, Alberto Larghi, Roberto Persiani and 1 more

Open access · bronzeAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 66 citations in OpenAlex.

  1. Gastric Adenomas and Mimickers: A Review.Diagnostics (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. [Gastrointestinal stromal tumors : Where do we stand?]Pathologie (Heidelberg, Germany) · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Riccardo RicciDepartment of Pathology, Catholic University, Rome, Italy.
Maurizio MartiniDepartment of Pathology, Catholic University, Rome, Italy.ORCID 0000000262606310
Tonia CenciDepartment of Pathology, Catholic University, Rome, Italy.
Arnaldo CarboneDepartment of Pathology, Catholic University, Rome, Italy.
Paola LanzaDepartment of Pathology, Catholic University, Rome, Italy.
Alberto BiondiDepartment of Surgery, Catholic University, Rome, Italy.
Guido RindiDepartment of Pathology, Catholic University, Rome, Italy.
Alessandra CassanoDepartment of Oncology, Catholic University, Rome, Italy.
Alberto LarghiDepartment of Digestive Endoscopy, Catholic University, Rome, Italy.
Roberto PersianiDepartment of Surgery, Catholic University, Rome, Italy.
Luigi M LaroccaDepartment of Pathology, Catholic University, Rome, Italy.
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germline PDGFRA mutations cause multiple heterogeneous gastrointestinal mesenchymal tumors. In its familial form this disease, which was formerly termed intestinal neurofibromatosis/neurofibromatosis 3b (INF/NF3b), has been included among familial gastrointestinal stromal tumors (GISTs) because of its genotype, described when GIST was the only known PDGFRA-mutant gastrointestinal tumor. Shortly afterwards, however, inflammatory fibroid polyps also revealed PDGFRA mutations. Subsequently, gastrointestinal CD34+ 'fibrous tumors' of uncertain classification were described in a germline PDGFRA-mutant context. Our aim was to characterize the syndrome produced by germline PDGFRA mutations and establish diagnostic criteria and management strategies for this hitherto puzzling disease. We studied a kindred displaying multiple gastrointestinal mesenchymal tumors, comparing it with published families/individuals with possible analogous conditions. We identified a novel inherited PDGFRA mutation (P653L), constituting the third reported example of familial PDGFRA mutation. In adult mutants we detected inflammatory fibroid polyps, gastric GISTs and gastrointestinal fibrous tumors of uncertain nosology. We demonstrate that the syndrome formerly defined as INF/NF3b (exemplified by the family reported herein) is simplistically considered a form of familial GIST, because inflammatory fibroid polyps often prevail. Fibrous tumors appear variants of inflammatory fibroid polyps. 'INF/NF3b' and 'familial GIST' are misleading terms which we propose changing to 'PDGFRA-mutant syndrome'. In this condition, unlike KIT-dependent familial GIST syndromes, if present, GISTs are stomach-restricted and diffuse Cajal cell hyperplasia is not observed. This restriction of GISTs to the stomach in PDGFRA-mutant syndrome: (i) focuses oncological concern on gastric masses, as inflammatory fibroid polyps are benign; (ii) supports a selective role of gastric environment for PDGFRA mutations to elicit GISTs, justifying the known predilection for stomach of sporadic PDGFRA-mutant GISTs. An awareness that inflammatory fibroid polyps, relatively common among gastrointestinal mesenchymal tumors, may be the prevailing tumor in PDGFRA-mutant syndrome could eventually reveal an unsuspected prevalence of this condition.

Indexed as

MutationAdultAgedColonic PolypsFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansMaleMiddle AgedPedigreeReceptor, Platelet-Derived Growth Factor alphaSyndromeReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID25975287
OpenAlexW1539540482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.